Live
FierceBiotechLilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammalsFierceBiotechAstraZeneca to build cell therapy manufacturing hub, R&D center in ShanghaiFierceBiotechMiniMed claims FDA clearance for small, screen-free insulin pumpFierceBiotechPhage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sectorFierceBiotechSyneos Health scoops up Chinese CRO to secure place in ‘rapidly growing market’BioPharma DivePfizer aims for wider use of PARP drug in prostate cancer with new dataEndpoints NewsAstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plansEndpoints NewsCollegium is acquiring Corium's approved ADHD drug for $650MEndpoints NewsPfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 winBioPharma DiveA biotech VC sees early signs of a turnaround for startupsEndpoints NewsWashington’s Medicaid program will pay for ElliQ, an AI robot for lonelinessBioWorldInnocare presents new VAV1 degradation inducers
Endpoints News Jan 27, 2026

AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal

AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal

Original
Body unavailable. Use the original source.

Directory

59 All